Aguirre, M. & Collins, M.D. (1993). Lactic acid bacteria and human clinical infections. J. Appl. Bact. 75:95-107.
Bartosch, S., Woodmansey, E.J., Paterson, J.C.M., McMurdo, M.E.T. & Macfarlane, G.T. (2005). Microbiological effects of consuming a symbiotic containing Bifidobacterium bifidum, bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerise chain reaction and counting of viable bacteria. Clinical Infectious Diseases. 40:28-37.
Boyle, R.J., Robins-Browne, R.M. & Tang, M.L. (2006). Probiotic use in clinical practice: what are the risks? Am J. Clin Nutr. 83(6):1256-64.
Borriello, S.R, Hammes, W.P.,, Holzapfel, W., Marteau, P, Schrezenmeir, J., Vaara, M. & Valtonen, V. (2008). Safety of probiotics that contain lactobacilli or bifidobacteria. Clin. Infect Dis. 36:775-780.
Buda, A., Qualtrough, D., Jepson, M.A., Martines, D., Paraskeva, C., Pignatelli, M. Butyrate downregulates a2ß1 integrin: a possible role in the induction of apoptosis in colorectal cancer cell lines. Article in Gut • (2003)52: pp. 729–734.
Delcour, J., Ferain, T., Deghorain, M., Palumbo, E. & Hols, P. (1999). The biosynthesis and functionality of the cellwall of lactic acid bacteria. Antonie Van Leeuwenhoek. 76(1-4):159-84.15. slide
Di Sabatino A, Morera R, Ciccocioppo R, Cazzola P, Gotti S, Tinozzi FP, Tinozzi S, Corazza GR. Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol Ther. 2005 Nov 1;22(9):789-94. doi: 10.1111/j.1365-2036.2005.02639.x. PMID: 16225487.
Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A., & Pot, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology. 13(2):236-243.
Gaudier, E., Jarry, A., Blottie`re, H.M., De Coppet, P., Buisine, M.P., Aubert, J.P., Laboisse, C., Cherbut, C., and Hoebler, C., Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am J Physiol Gastrointest Liver Physiol.( 2004) 287: pp. G1168–G1174.
Hallert, C., Björck, I., Nyman, M., Pousette, A., Grännö, C. and Svensson, H. Increasing Fecal Butyrate in Ulcerative Colitis Patients by Diet: Controlled Pilot Study. Inflammatory Bowel Diseases; Crohn’s & Colitis Foundation of America, (2003) pp. 116–121.
Lammers, K.M., Brigidi, P., Vitali, B., Gionchetti, P, Rizello, F, Caramelli, E., Matteuzzi, D. & Campieri, M. (2003). Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunology and Medical Microbiology. 38:165-172.
Masco, L., Ventura, M., Zink, R., Huys, G. & Swings, J. (2004). Polyphasic taxonomic analysis of Bifidobacterium animalis and Bifidobacterium lactis reveals relatedness at the subspecies level: reclassification of Bifidobacterium animalis subsp. Animalis subsp. nov. and Bifidobacterium lactis as Bifidobacterium animalis subsp. Lactis subsp. nov. Int. J. Syste. Evol. Microbiol. 54:1137-1143.
Meile, L., Ludwig, W., Rueger, U., Gut, C., Kaufmann, P, Dasen, G., Wenger, S. & Teuber, M. (1997). Bifidobacterium lactis sp. nov., a moderately oxygen tolerant species isolated from fermented milk. Syst. Appl. Microbiol. 20:57-64.
Mitsuoka, T. (1996). Intestinal flora and human health. Asia Pacific J.Clin. Nutr. 5:2-9.
Resta-Lenert, S., Truong, F., Barrett, K.E. and Eckmann I. Inhibition of epithelial chloride secretion by butyrate: role of reduced adenylyl cyclase expression and activity. Am J Physiol Cell Physiol (2001) 281: pp. C1837–C1849.
Ruemmele, F.M., Schwartz, S., Seidman, E.G., Dionne, S., Levy, E., Lentze, M.J. Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway. Gut (2003);52: pp.94–100.
Salminen, S., von Wright, A., Morelli, L., Marteau, P., Brassart, D., de Vos, W.M., Fonden, R., Saxelin, M., Collins, K., Mogensen, G., Birkeland, S.-E. & Mattila- Sandholm, T. (1998). Demonstration of safety of probiotics-a review. Int. J. Food Prot. 44:93-106.
